Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of TriAdeno Vaccine With N-803 in Localized Prostate Cancer
NCT07574541Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept in prostate cancer (PCa), sponsored by National Cancer Institute. Started Nov 2026; status: recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07574541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07574541.